GAITHERSBURG, Md., Dec 18, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced that it has completed its sale of CytoGam(R)
(cytomegalovirus immune globulin intravenous (human)) to ZLB Behring. As
specified in the agreement executed November 8, 2006, ZLB Behring has made a
one-time upfront payment of $50 million to MedImmune, plus equipment and
inventory payments, for full worldwide rights to CytoGam. Further, an
additional $70 million may be paid to MedImmune by ZLB Behring upon
achievement of certain cumulative net sales milestones.
CytoGam is an intravenous immune globulin enriched in antibodies against
cytomegalovirus (CMV). It is used to prevent CMV disease associated with
transplantation of the kidney, lung, liver, pancreas and heart.
CytoGam is indicated for the prophylaxis of cytomegalovirus disease
associated with transplantation of kidney, lung, liver, pancreas and heart. In
transplants of these organs other than kidney from CMV seropositive donors
into seronegative recipients, prophylactic CMV-IGIV should be considered in
combination with ganciclovir.
CytoGam is made from human plasma and like other plasma products carries
the possibility for transmission of blood-borne viral agents. CytoGam should
not be used in individuals with a history of a prior severe reaction to
CytoGam or other human immunoglobulins. Immune Globulin Intravenous (Human)
products have been reported to be associated with renal dysfunction, acute
renal failure, osmotic nephrosis, and death. CytoGam contains sucrose as a
stabilizer. In patients predisposed to acute renal failure, IGIV products
should be administered at the minimum concentrations available and the minimum
rate of infusion practical. Severe reactions such as angioneurotic edema and
anaphylactic shock, although not observed during clinical trials, are a
possibility. Minor reactions such as flushing, chills, muscle cramps, back
pain, fever, nausea, vomiting, arthralgia, and wheezing were the most frequent
adverse reactions observed during clinical trials. For more information,
please download a package insert at
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,500 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.